![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information)
15MB |
| Item Type: | Article |
|---|---|
| Title: | Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer |
| Creators Name: | Schaufler, D., Ast, D.F., Tumbrink, H.L., Abedpour, N., Maas, L., Schwäbe, A.E., Spille, I., Lennartz, S., Fassunke, J., Aldea, M., Besse, B., Planchard, D., Nogova, L., Michels, S., Kobe, C., Persigehl, T., Westphal, T., Koleczko, S., Fischer, R., Weber, J.P., Altmüller, J., Thomas, R.K., Merkelbach-Bruse, S., Gautschi, O., Mezquita, L., Büttner, R., Wolf, J., Peifer, M., Brägelmann, J., Scheffler, M. and Sos, M.L. |
| Abstract: | Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients. However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR therapy remains elusive. We tracked the evolution of subclonal mutations by whole-exome sequencing and performed clonal analyses of individual metastases during therapy. Complementary functional analyses of polyclonal EGFR-mutant cell pools showed a dose-dependent enrichment of BRAF(V600E) and a loss of EGFR inhibitor susceptibility. The clones remain stable and become vulnerable to combined EGFR, RAF, and MEK inhibition. Moreover, only osimertinib/trametinib combination treatment, but not monotherapy with either of these drugs, leads to robust tumor shrinkage in EGFR-driven xenograft models harboring BRAF mutations. These data provide insights into the dynamics of clonal evolution of EGFR-mutant tumors and the therapeutic implications of BRAF(V600E) co-mutations that may facilitate the development of treatment strategies to improve the prognosis of these patients. |
| Keywords: | Animals, Mice |
| Source: | npj Precision Oncology |
| ISSN: | 2397-768X |
| Publisher: | Springer Nature |
| Volume: | 5 |
| Number: | 1 |
| Page Range: | 102 |
| Date: | 17 December 2021 |
| Official Publication: | https://doi.org/10.1038/s41698-021-00241-9 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
